The Oncologist
-
Publication Venue For
- Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. 24:989-996. 2019
- Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.. 24:648-656. 2019
- Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.. 23:328-336. 2018
- Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting.. 21:731-738. 2016
- Reducing tobacco-related cancer incidence and mortality: summary of an institute of medicine workshop.. 19:21-31. 2014
- The Role of Brachyury in Notochordal and Non-Notochordal Malignancy. 18:S1-S1. 2013
- A Pilot Randomized Controlled Trial of Brief Cognitive-Behavioral Therapy for Anxiety in Patients with Terminal Cancer. 17:1337-1345. 2012
- Beyond costs and benefits: understanding how patients make health care decisions.. 15 Suppl 1:5-10. 2010
- Malignancy after solid organ transplantation: an overview.. 13:769-778. 2008
- Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.. 13:515-525. 2008
- The ethical justification for minor sibling bone marrow donation: a case study.. 13:148-151. 2008
- Commentary: rectal cancer an evolution of treatment.. 12:1319-1320. 2007
- Extended resection for pancreatic adenocarcinoma.. 12:654-663. 2007
- Anal cancer: an overview.. 12:524-534. 2007
- Salvage therapy in Hodgkin's lymphoma.. 12:156-167. 2007
- Thymoma: benign appearance, malignant potential.. 11:887-894. 2006
- Hairy cell leukemia: an elusive but treatable disease.. 11:780-789. 2006
- Risk models for predicting chemotherapy-induced neutropenia.. 10:427-437. 2005
- New combinations in metastatic colorectal cancer: what are our expectations?. 10:320-322. 2005
- Never too old? Age should not be a barrier to enrollment in cancer clinical trials.. 10:198-204. 2005
- Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.. 10 Suppl 3:30-39. 2005
- Introduction: Targeting angiogenesis in cancer therapy. 9:1. 2004
- Conformal radiation therapy for childhood CNS tumors.. 9:442-450. 2004
- Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. 9 Suppl 5:31-40. 2004
- Targeted therapy of colorectal cancer: clinical experience with bevacizumab.. 9 Suppl 1:11-18. 2004
- rHuEPO and improved treatment outcomes: potential modes of action.. 9 Suppl 5:41-47. 2004
- Activation of tyrosine kinases in cancer.. 8:531-538. 2003
- Interpreting measures of treatment effect in cancer clinical trials.. 7:181-187. 2002
- Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.. 6 Suppl 1:20-24. 2001
- MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer.. 5:108-114. 2000
- Research and quality medicine in the community: The paradigm of marrow transplantation. 3:354-356. 1998
- Imaging Approaches in Oncology: Update on PET/CT 2012